Cargando…
Staphylococcal Enterotoxin C2 Mutant-Induced Antitumor Immune Response Is Controlled by CDC42/MLC2-Mediated Tumor Cell Stiffness
As a biological macromolecule, the superantigen staphylococcal enterotoxin C2 (SEC2) is one of the most potent known T-cell activators, and it induces massive cytotoxic granule production. With this property, SEC2 and its mutants are widely regarded as immunomodulating agents for cancer therapy. In...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380429/ https://www.ncbi.nlm.nih.gov/pubmed/37511553 http://dx.doi.org/10.3390/ijms241411796 |
_version_ | 1785080191527157760 |
---|---|
author | Fu, Xuanhe Xu, Mingkai Yu, Zhixiong Gu, Wu Zhang, Zhichun Zhang, Bowen Wang, Xiujuan Su, Zhencheng Zhang, Chenggang |
author_facet | Fu, Xuanhe Xu, Mingkai Yu, Zhixiong Gu, Wu Zhang, Zhichun Zhang, Bowen Wang, Xiujuan Su, Zhencheng Zhang, Chenggang |
author_sort | Fu, Xuanhe |
collection | PubMed |
description | As a biological macromolecule, the superantigen staphylococcal enterotoxin C2 (SEC2) is one of the most potent known T-cell activators, and it induces massive cytotoxic granule production. With this property, SEC2 and its mutants are widely regarded as immunomodulating agents for cancer therapy. In a previous study, we constructed an MHC-II-independent mutant of SEC2, named ST-4, which exhibits enhanced immunocyte stimulation and antitumor activity. However, tumor cells have different degrees of sensitivity to SEC2/ST-4. The mechanisms of immune resistance to SEs in cancer cells have not been investigated. Herein, we show that ST-4 could activate more powerful human lymphocyte granule-based cytotoxicity than SEC2. The results of RNA-seq and atomic force microscopy (AFM) analysis showed that, compared with SKOV3 cells, the softer ES-2 cells could escape from SEC2/ST-4-induced cytotoxic T-cell-mediated apoptosis by regulating cell softness through the CDC42/MLC2 pathway. Conversely, after enhancing the stiffness of cancer cells by a nonmuscle myosin-II-specific inhibitor, SEC2/ST-4 exhibited a significant antitumor effect against ES-2 cells by promoting perforin-dependent apoptosis and the S-phase arrest. Taken together, these data suggest that cell stiffness could be a key factor of resistance to SEs in ovarian cancer, and our findings may provide new insight for SE-based tumor immunotherapy. |
format | Online Article Text |
id | pubmed-10380429 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103804292023-07-29 Staphylococcal Enterotoxin C2 Mutant-Induced Antitumor Immune Response Is Controlled by CDC42/MLC2-Mediated Tumor Cell Stiffness Fu, Xuanhe Xu, Mingkai Yu, Zhixiong Gu, Wu Zhang, Zhichun Zhang, Bowen Wang, Xiujuan Su, Zhencheng Zhang, Chenggang Int J Mol Sci Article As a biological macromolecule, the superantigen staphylococcal enterotoxin C2 (SEC2) is one of the most potent known T-cell activators, and it induces massive cytotoxic granule production. With this property, SEC2 and its mutants are widely regarded as immunomodulating agents for cancer therapy. In a previous study, we constructed an MHC-II-independent mutant of SEC2, named ST-4, which exhibits enhanced immunocyte stimulation and antitumor activity. However, tumor cells have different degrees of sensitivity to SEC2/ST-4. The mechanisms of immune resistance to SEs in cancer cells have not been investigated. Herein, we show that ST-4 could activate more powerful human lymphocyte granule-based cytotoxicity than SEC2. The results of RNA-seq and atomic force microscopy (AFM) analysis showed that, compared with SKOV3 cells, the softer ES-2 cells could escape from SEC2/ST-4-induced cytotoxic T-cell-mediated apoptosis by regulating cell softness through the CDC42/MLC2 pathway. Conversely, after enhancing the stiffness of cancer cells by a nonmuscle myosin-II-specific inhibitor, SEC2/ST-4 exhibited a significant antitumor effect against ES-2 cells by promoting perforin-dependent apoptosis and the S-phase arrest. Taken together, these data suggest that cell stiffness could be a key factor of resistance to SEs in ovarian cancer, and our findings may provide new insight for SE-based tumor immunotherapy. MDPI 2023-07-22 /pmc/articles/PMC10380429/ /pubmed/37511553 http://dx.doi.org/10.3390/ijms241411796 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fu, Xuanhe Xu, Mingkai Yu, Zhixiong Gu, Wu Zhang, Zhichun Zhang, Bowen Wang, Xiujuan Su, Zhencheng Zhang, Chenggang Staphylococcal Enterotoxin C2 Mutant-Induced Antitumor Immune Response Is Controlled by CDC42/MLC2-Mediated Tumor Cell Stiffness |
title | Staphylococcal Enterotoxin C2 Mutant-Induced Antitumor Immune Response Is Controlled by CDC42/MLC2-Mediated Tumor Cell Stiffness |
title_full | Staphylococcal Enterotoxin C2 Mutant-Induced Antitumor Immune Response Is Controlled by CDC42/MLC2-Mediated Tumor Cell Stiffness |
title_fullStr | Staphylococcal Enterotoxin C2 Mutant-Induced Antitumor Immune Response Is Controlled by CDC42/MLC2-Mediated Tumor Cell Stiffness |
title_full_unstemmed | Staphylococcal Enterotoxin C2 Mutant-Induced Antitumor Immune Response Is Controlled by CDC42/MLC2-Mediated Tumor Cell Stiffness |
title_short | Staphylococcal Enterotoxin C2 Mutant-Induced Antitumor Immune Response Is Controlled by CDC42/MLC2-Mediated Tumor Cell Stiffness |
title_sort | staphylococcal enterotoxin c2 mutant-induced antitumor immune response is controlled by cdc42/mlc2-mediated tumor cell stiffness |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380429/ https://www.ncbi.nlm.nih.gov/pubmed/37511553 http://dx.doi.org/10.3390/ijms241411796 |
work_keys_str_mv | AT fuxuanhe staphylococcalenterotoxinc2mutantinducedantitumorimmuneresponseiscontrolledbycdc42mlc2mediatedtumorcellstiffness AT xumingkai staphylococcalenterotoxinc2mutantinducedantitumorimmuneresponseiscontrolledbycdc42mlc2mediatedtumorcellstiffness AT yuzhixiong staphylococcalenterotoxinc2mutantinducedantitumorimmuneresponseiscontrolledbycdc42mlc2mediatedtumorcellstiffness AT guwu staphylococcalenterotoxinc2mutantinducedantitumorimmuneresponseiscontrolledbycdc42mlc2mediatedtumorcellstiffness AT zhangzhichun staphylococcalenterotoxinc2mutantinducedantitumorimmuneresponseiscontrolledbycdc42mlc2mediatedtumorcellstiffness AT zhangbowen staphylococcalenterotoxinc2mutantinducedantitumorimmuneresponseiscontrolledbycdc42mlc2mediatedtumorcellstiffness AT wangxiujuan staphylococcalenterotoxinc2mutantinducedantitumorimmuneresponseiscontrolledbycdc42mlc2mediatedtumorcellstiffness AT suzhencheng staphylococcalenterotoxinc2mutantinducedantitumorimmuneresponseiscontrolledbycdc42mlc2mediatedtumorcellstiffness AT zhangchenggang staphylococcalenterotoxinc2mutantinducedantitumorimmuneresponseiscontrolledbycdc42mlc2mediatedtumorcellstiffness |